BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Better together……MEDI0382 a novel combination biologic drug fo
 r Type 2 diabetes (POSTPONED) - Dr Matthew Coghlan (MedImmune / AstraZenec
 a)
DTSTART:20170303T174500Z
DTEND:20170303T191000Z
UID:TALK70734@talks.cam.ac.uk
CONTACT:Dr Antonio M. M. Rodrigues
DESCRIPTION:The global prevalence of Type 2 diabetes is increasing at an a
 larming rate. This escalation is driven in large part by increased body we
 ight as societies adopt a “Western” lifestyle. Current anti-diabetic m
 edicines have little or no effect to reduce excess body weight. MEDI0382 i
 s a molecule conceived of in an attempt to generate a novel drug for Type 
 2 diabetes that would deliver both effective glucose control and significa
 nt weight loss. This molecule is a dual agonist peptide that activates bot
 h the glucagon like peptide-1 (GLP1) receptor and the glucagon receptor (G
 CG)\, thereby combining their complementary pharmacological effects to low
 er blood glucose\, suppress food intake and increase energy expenditure. T
 he story of the research that led to the discovery of MEDI0382 and its cha
 racterisation in preclinical models will be presented.
LOCATION:Wolfson College\, Gatsby Room
END:VEVENT
END:VCALENDAR